KH2014 Suositus KH2014 Suositus

Tulosta

Suosituksessa käytettyjä tutkimushankkeiden lyhenteitä (lähinnä lääketutkimuksia)

Lisätietoa aiheesta
4.3.2013
Timo Strandberg
Lyhenne Selite Kirjallisuusviite
AFCAPS/TexCAPS Air Force / Texas Coronary Atherosclerosis Prevention Study «Downs JR, Clearfield M, Weis S ym. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Ath»1
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial «ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholest»2
ALERT Assessment of Lescol in Renal Transplantation «Holdaas H, Fellström B, Jardine AG ym. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31 »3
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial «Sever PS, Dahlöf B, Poulter NR ym. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-S»4
ASPEN Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus «Knopp RH, d'Emden M, Smilde JG ym. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronar»5
A to Z Aggrastat-to-Zocor trial «de Lemos JA, Blazing MA, Wiviott SD ym. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16 »6
BECAIT Bezafibrate Coronary Atherosclerosis Intervention Trial «Ericsson CG, Hamsten A, Nilsson J ym. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53 »7
BIP Bezafibrate Infarction Prevention «Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7 »8
CARDS Collaborative Atorvastatin Diabetes Study «Colhoun HM, Betteridge DJ, Durrington PN ym. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre ran»9
CARE Cholesterol And Recurrent Events «Sacks FM, Pfeffer MA, Moye LA ym. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investiga»10
CORONA Controlled rosuvastatin multinational study in heart failure «Kjekshus J, Apetrei E, Barrios V ym. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61 »11
CDP Coronary Drup Project «Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81 »12
DAIS Diabetes Atherosclerosis Intervention Study «Ansquer JC, Foucher C, Rattier S ym. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Interv»13
DASH Dietary Approaches to Stop Hypertension «Fung TT, Chiuve SE, McCullough ML ym. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008;168:713-20 »14
ENHANCE Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression «Kastelein JJ, Akdim F, Stroes ES ym. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43 »15
EUROASPIRE European Action on Secondary Prevention through Intervention to Reduce Events «De Bacquer D, De Backer G, Ostör E ym. Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil 2003;10:»16
GISSI-HF Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico – Heart failure «Gissi-HF Investigators, Tavazzi L, Maggioni AP ym. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008»17
GREACE Greek Atorvastatin and Coronary-heart-disease Evaluation «Athyros VG, Papageorgiou AA, Mercouris BR ym. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The G»18
HPS Heart Protection Study «Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;»19
HHS Helsinki Heart Study «Frick MH, Syvänne M, Nieminen MS ym. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL ch»20
IDEAL Incremental Decrease in End Points through Aggressive Lipid-Lowering trial «Pedersen TR, Faergeman O, Kastelein JJ ym. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2»21
IMPROVE-IT Improved reduction of outcomes: vytorin™ efficacy international trial «Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103). (Online http://www.clinicaltrials.gov/ct/show/NCT00202878) 26.10.08»22
LIPID Long-term Intervention with Pravastatin in Ischemic Disease «Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in I»23
JUPITER Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin «Ridker PM, Danielson E, Fonseca FA ym. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207 »24
LIPS Lescol Intervention Prevention Study «Serruys PW, de Feyter P, Macaya C ym. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22 »25
LOCAT Lopid Coronary Angiography Trial «Frick MH, Syvänne M, Nieminen MS ym. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL ch»26
LRC-CPPT Lipid Research Clinics - Cholestyramine Primary Prevention Trial «The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64 »27
METEOR Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin «Crouse JR 3rd, Raichlen JS, Riley WA ym. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;2»28
MIRACL Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering «Schwartz GG, Olsson AG, Ezekowitz MD ym. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8 »29
PROSPER Prospective Study of Pravastatin in the Elderly at Risk «Shepherd J, Blauw GJ, Murphy MB ym. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30 »30
PROVE-IT Pravastatin or Atorvastatin Evaluation and Infarction Therapy – Thrombolysis In Myocardial Infarction – 22 trial «Cannon CP, McCabe CH, Belder R ym. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-1 »31
SCORE Systematic Coronary Risk Evaluation «Conroy RM, Pyörälä K, Fitzgerald AP ym. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003 »32
SEAS Simvastatin and ezetimibe in aortic stenosis «Rossebø AB, Pedersen TR, Allen C ym. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970-3 »33
SHARP Study of heart and renal protection «Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;:S207-10 »34
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels «Amarenco P, Goldstein LB, Szarek M ym. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduct»35
TNT Treat to New Targets trial «LaRosa JC, Grundy SM, Waters DD ym. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 »36
VA-HIT Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial «Bloomfield Rubins H, Davenport J, Babikian V ym. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). »37
WOSCOPS West Of Scotland Coronary Prevention Study «Shepherd J, Cobbe SM, Ford I ym. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7 »38
4S Scandinavian Simvastatin Survival Study «Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9 »39

Kirjallisuutta

  1. Downs JR, Clearfield M, Weis S ym. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22 «PMID: 9613910»PubMed
  2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007 «PMID: 12479764»PubMed
  3. Holdaas H, Fellström B, Jardine AG ym. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31 «PMID: 12814712»PubMed
  4. Sever PS, Dahlöf B, Poulter NR ym. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58 «PMID: 12686036»PubMed
  5. Knopp RH, d'Emden M, Smilde JG ym. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85 «PMID: 16801565»PubMed
  6. de Lemos JA, Blazing MA, Wiviott SD ym. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16 «PMID: 15337732»PubMed
  7. Ericsson CG, Hamsten A, Nilsson J ym. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53 «PMID: 8622389»PubMed
  8. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7 «PMID: 10880410»PubMed
  9. Colhoun HM, Betteridge DJ, Durrington PN ym. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96 «PMID: 15325833»PubMed
  10. Sacks FM, Pfeffer MA, Moye LA ym. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9 «PMID: 8801446»PubMed
  11. Kjekshus J, Apetrei E, Barrios V ym. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61 «PMID: 17984166»PubMed
  12. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81 «PMID: 1088963»PubMed
  13. Ansquer JC, Foucher C, Rattier S ym. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-93 «PMID: 15754270»PubMed
  14. Fung TT, Chiuve SE, McCullough ML ym. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008;168:713-20 «PMID: 18413553»PubMed
  15. Kastelein JJ, Akdim F, Stroes ES ym. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43 «PMID: 18376000»PubMed
  16. De Bacquer D, De Backer G, Ostör E ym. Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil 2003;10:289-95 «PMID: 14555885»PubMed
  17. Gissi-HF Investigators, Tavazzi L, Maggioni AP ym. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9 «PMID: 18757089»PubMed
  18. Athyros VG, Papageorgiou AA, Mercouris BR ym. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8 «PMID: 12201623»PubMed
  19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 «PMID: 12114036»PubMed
  20. Frick MH, Syvänne M, Nieminen MS ym. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43 «PMID: 9337181»PubMed
  21. Pedersen TR, Faergeman O, Kastelein JJ ym. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45 «PMID: 16287954»PubMed
  22. Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103). (Online http://www.clinicaltrials.gov/ct/show/NCT00202878) 26.10.08
  23. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57 «PMID: 9841303»PubMed
  24. Ridker PM, Danielson E, Fonseca FA ym. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207 «PMID: 18997196»PubMed
  25. Serruys PW, de Feyter P, Macaya C ym. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22 «PMID: 12076217»PubMed
  26. Frick MH, Syvänne M, Nieminen MS ym. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43 «PMID: 9337181»PubMed
  27. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64 «PMID: 6361299»PubMed
  28. Crouse JR 3rd, Raichlen JS, Riley WA ym. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344-53 «PMID: 17384434»PubMed
  29. Schwartz GG, Olsson AG, Ezekowitz MD ym. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8 «PMID: 11277825»PubMed
  30. Shepherd J, Blauw GJ, Murphy MB ym. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30 «PMID: 12457784»PubMed
  31. Cannon CP, McCabe CH, Belder R ym. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-1 «PMID: 11909576»PubMed
  32. Conroy RM, Pyörälä K, Fitzgerald AP ym. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003 «PMID: 12788299»PubMed
  33. Rossebø AB, Pedersen TR, Allen C ym. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970-3 «PMID: 17398194»PubMed
  34. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;:S207-10 «PMID: 12694346»PubMed
  35. Amarenco P, Goldstein LB, Szarek M ym. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-204 «PMID: 17962589»PubMed
  36. LaRosa JC, Grundy SM, Waters DD ym. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 «PMID: 15755765»PubMed
  37. Bloomfield Rubins H, Davenport J, Babikian V ym. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33 «PMID: 11401940»PubMed
  38. Shepherd J, Cobbe SM, Ford I ym. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7 «PMID: 7566020»PubMed
  39. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9 «PMID: 7968073»PubMed
Käypä hoito -suositukset ovat riippumattomia, tutkimusnäyttöön perustuvia kansallisia hoitosuosituksia. Lue lisää
KÄYPÄ HOITO -SUOSITUS Dyslipidemiat
LINKKIEN TYYPIT JA VÄRIKOODIT
Kirjallisuusviite
Kuva
Linkki toiselle sivustolle
Lisätietoa
Näytönastekatsaus
PDF-tiedosto
PubMed-abstrakti
Taulukko